Baidu
map

Lancet Glob Health:孕前感染乙肝增加早产风险

2017-05-23 佚名 健康报

近日,国际著名医学期刊《柳叶刀·全球卫生》在线发表了北京大学公共卫生学院刘民教授课题组与国家卫生计生委妇幼健康服务司合作完成的一项大规模人群队列研究成果。该项研究发现,女性孕前乙肝病毒(HBV)感染增加了早产的风险。

近日,国际著名医学期刊《柳叶刀·全球卫生》在线发表了北京大学公共卫生学院刘民教授课题组与国家卫生计生委妇幼健康服务司合作完成的一项大规模人群队列研究成果。该项研究发现,女性孕前乙肝病毒(HBV)感染增加了早产的风险。

刘民介绍,早产是导致围产儿死亡以及新生儿严重并发症的最常见原因,也是 5 岁以下儿童死亡的主要原因之一。HBV 感染是全球主要的公共卫生问题之一,导致了较高的死亡率和社会负担。西方国家的大样本队列研究发现,妇女 HBV 感染与早产有关,但中国作为 HBV 感染的高负担国家,尚缺乏此类证据。

刘民课题组利用 2010 年~2012 年国家免费孕前优生项目中 31 个省份 220 个县的 489965 名育龄女性孕前健康体检以及妊娠结局随访数据,采用队列研究的方法,探讨了妇女孕前乙肝病毒感染与子代早产风险之间的关系。国家免费孕前优生项目于 2010 年启动,旨在为半年内计划怀孕的农村育龄夫妇提供免费孕前健康检查和孕前优生咨询,并随访至妊娠结局。研究结果显示,孕前未感染 HBV 组、HBsAg(乙肝表面抗原)阳性但 HBeAg(乙肝 e 抗原)阴性组、HBsAg 和 HBeAg 同时阳性组的早产率(孕周小于 37 周)分别为 5.2%、6.5% 和 6.2%,早期早产率(孕周小于 34 周)分别为 1.4%、1.7% 和 1.9%。与未感染 HBV 的妇女相比,妇女孕前 HBsAg 阳性但 HBeAg 阴性者的早产和早期早产风险分别增加了 26% 和 18%;HBsAg 和 HBeAg 同时阳性者的早产和早期早产风险分别增加了 20% 和 34%。

刘民说,研究结果提示,除了关注乙肝感染的母婴传播风险外,HBV 感染孕妇的早产风险也不应被忽视。孕前筛查 HBV 以及在孕前及孕期对 HBV 感染者进行适当的医学干预,对降低早产风险、改善母婴结局、减少儿童死亡率具有重要意义。

原始出处:

Liu J, Zhang S, Liu M, et al. Maternal pre-pregnancy infection with hepatitis B virus and the risk of preterm birth: a population-based cohort study. Lancet Glob Health. 2017 Jun;5(6):e624-e632. doi: 10.1016/S2214-109X(17)30142-0.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1828964, encodeId=03f71828964c4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Mar 04 19:17:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861090, encodeId=fb43186109066, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 10 13:17:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659573, encodeId=657316595e33d, content=<a href='/topic/show?id=c42845239ef' target=_blank style='color:#2F92EE;'>#孕前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45239, encryptionId=c42845239ef, topicName=孕前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8925003801, createdName=szhvet, createdTime=Fri Dec 22 09:17:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207766, encodeId=215620e76618, content=以后在临床要注意了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa562069713, createdName=1361efd61am, createdTime=Wed Jun 07 15:40:43 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621606, encodeId=23ba162160626, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu May 25 00:17:00 CST 2017, time=2017-05-25, status=1, ipAttribution=)]
    2018-03-04 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1828964, encodeId=03f71828964c4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Mar 04 19:17:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861090, encodeId=fb43186109066, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 10 13:17:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659573, encodeId=657316595e33d, content=<a href='/topic/show?id=c42845239ef' target=_blank style='color:#2F92EE;'>#孕前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45239, encryptionId=c42845239ef, topicName=孕前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8925003801, createdName=szhvet, createdTime=Fri Dec 22 09:17:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207766, encodeId=215620e76618, content=以后在临床要注意了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa562069713, createdName=1361efd61am, createdTime=Wed Jun 07 15:40:43 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621606, encodeId=23ba162160626, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu May 25 00:17:00 CST 2017, time=2017-05-25, status=1, ipAttribution=)]
    2017-09-10 shizhenshan
  3. [GetPortalCommentsPageByObjectIdResponse(id=1828964, encodeId=03f71828964c4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Mar 04 19:17:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861090, encodeId=fb43186109066, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 10 13:17:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659573, encodeId=657316595e33d, content=<a href='/topic/show?id=c42845239ef' target=_blank style='color:#2F92EE;'>#孕前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45239, encryptionId=c42845239ef, topicName=孕前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8925003801, createdName=szhvet, createdTime=Fri Dec 22 09:17:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207766, encodeId=215620e76618, content=以后在临床要注意了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa562069713, createdName=1361efd61am, createdTime=Wed Jun 07 15:40:43 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621606, encodeId=23ba162160626, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu May 25 00:17:00 CST 2017, time=2017-05-25, status=1, ipAttribution=)]
    2017-12-22 szhvet
  4. [GetPortalCommentsPageByObjectIdResponse(id=1828964, encodeId=03f71828964c4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Mar 04 19:17:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861090, encodeId=fb43186109066, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 10 13:17:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659573, encodeId=657316595e33d, content=<a href='/topic/show?id=c42845239ef' target=_blank style='color:#2F92EE;'>#孕前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45239, encryptionId=c42845239ef, topicName=孕前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8925003801, createdName=szhvet, createdTime=Fri Dec 22 09:17:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207766, encodeId=215620e76618, content=以后在临床要注意了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa562069713, createdName=1361efd61am, createdTime=Wed Jun 07 15:40:43 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621606, encodeId=23ba162160626, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu May 25 00:17:00 CST 2017, time=2017-05-25, status=1, ipAttribution=)]
    2017-06-07 1361efd61am

    以后在临床要注意了。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1828964, encodeId=03f71828964c4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Mar 04 19:17:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861090, encodeId=fb43186109066, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sun Sep 10 13:17:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659573, encodeId=657316595e33d, content=<a href='/topic/show?id=c42845239ef' target=_blank style='color:#2F92EE;'>#孕前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45239, encryptionId=c42845239ef, topicName=孕前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c8925003801, createdName=szhvet, createdTime=Fri Dec 22 09:17:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207766, encodeId=215620e76618, content=以后在临床要注意了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa562069713, createdName=1361efd61am, createdTime=Wed Jun 07 15:40:43 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621606, encodeId=23ba162160626, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu May 25 00:17:00 CST 2017, time=2017-05-25, status=1, ipAttribution=)]

相关资讯

中国艾滋乙肝合并感染分布图绘出

北京协和医院感染内科李太生教授团队绘制出中国艾滋病病毒—乙肝病毒共感染地区分布图,揭示出乙肝能加速艾滋病发展进程,合并感染不影响抗艾药物疗效和肝毒性,并探索出效优价廉的艾滋病病毒—乙肝共感染治疗新策略。围绕该项课题,团队已发表论文14篇,其中SCI论文10篇。研究结果被我国艾滋病诊疗指南引用;诊疗方案在广西、云南等艾滋病防治示范区推广应用,显着提高了治疗成功率。艾滋病和乙肝有相同感染途径,其他国家

乙肝患者生孩子 需要注意这些细节

现代医学关于乙肝母婴传播的阻断做的已经相当不错了,只要女性乙肝患者可以主意好这些细节,生一个健康宝宝并不是遥不可及的梦想。

J VIRAL HEPATITIS:中国农村近两百万备孕夫妇乙肝流行率现状

乙型肝炎病毒(HBV)感染是导致全球高死亡率和社会负担的主要健康问题。全球估计有20亿人感染HBV,其中2.46亿人为慢性感染,发生肝功能失代偿、肝硬化和肝细胞癌的风险增加。更为重要的是,中国的HBV感染负担居世界之最,估计有7460万HBsAg携带者。尽管过去二十年间,中国从HBV高流行率降至中度流行率,但HBV感染人群的绝对数量仍然非常大。尽管成功实施了婴幼儿普遍乙型肝炎疫苗接种计划,中国一直

Hepatology:乙肝治疗前后肝纤维化评估新分类

背景:纤维生成和纤维溶解动态变化的最终结果是肝脏纤维化。证据表明抗病毒治疗可逆转肝脏纤维化,甚或是HBV导致的早期肝硬化。然而,近期的评估系统主要关注纤维化的严重程度,而非其动态变化。方法:我们提出一种评估纤维化动态变化的新的分类:显着进展(厚/宽/疏松/分隔模糊伴炎症);显着逆转(着色浅/窄/致密/分隔)和表现为改善和退化瘢痕形成总体平衡的中间状态。然后,我们使用该分类评估恩替卡韦治疗前和治疗后

有没有资格献血也是个问题!

  今天发表的研究结果发现,来自德国无症状献血者的HEV RNA发生率高于之前报道的。 2017年在荷兰阿姆斯特丹举行的国际肝脏大会上的研究显示,测试的献血者中有0.11%是HEV RNA阳性(13,441个献血者中有15个),而无症状的HEV RNA阳性献血者中的一个先前已经捐赠了HEV RNA阳性血液制品,然后输入九个免疫受损患者体内。近年来,在献血中心对HEV RNA进行

Hepatology:乙肝肝移植术后恩替卡韦单药治疗长期预后

背景:慢性乙型肝炎(CHB)的患者肝移植后,长期抗病毒治疗对预防乙肝复发是必须的。方法:我们观察265例未使用乙肝免疫球蛋白(HBIG)恩替卡韦单一药物治疗的乙型肝炎(CHB)肝移植患者的长期预后。期间定期进行病毒血清学、病毒载量和肝脏生化指标检测。结果:中位随访时间为59个月。累积乙型肝炎表面抗原(HBsAg)血清学清除率在1年和5年时分别为90%和95%。1、3、5、8年HBsAg阴性率分别为

Baidu
map
Baidu
map
Baidu
map